Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Hayvanlarda Böbrek Hastalıklarının Erken Teşhisinde Biyobelirteç Olarak Proteomiklerin Önemi
The Importance of Proteomics as Biomarker in Early Diagnosis of Kidney Diseases in Animals
Eda ÜLKÜa, Ramazan YILDIZb
aBurdur Mehmet Akif Ersoy Üniversitesi Sağlık Bilimleri Enstitüsü, İç Hastalıkları ABD, Burdur, TÜRKİYE
bBurdur Mehmet Akif Ersoy Üniversitesi Veteriner Fakültesi, İç Hastalıkları ABD, Burdur, TÜRKİYE
Turkiye Klinikleri J Vet Sci. 2020;11(1):38-44
doi: 10.5336/vetsci.2019-72335
Article Language: TR
Full Text
ÖZET
 Böbrek yetmezlikleri, organ fonksiyonlarında azalma ile kendini gösteren; her yaştaki hayvanda, özellikle yaşlı hayvanlarda çok görülen önemli bir hastalıktır. Özellikle kronik böbrek yetmezliği, böbrek fonksiyonlarında geri dönüşümü olmayan azalma ile karakterizedir ve en fazla tespit edilen böbrek hastalığıdır. Böbrek hastalıklarında erken teşhis, etkili tedavi uygulamalarının yapılabilmesi açısından önem taşır. Kronik böbrek hastalığının tanısı, küçük hayvan pratiğinin önemli bir parçasıdır. Kreatinin, hastalığın erken teşhisinde yetersiz kalmaktadır. Günümüzde hastalıklar, toksik ajanlar ve ilaçların etkisiyle oluşan proteinlerin belirlenmesi ve işlevlerinin aydınlatılmasını amaçlayan birçok proteomik çalışma yapılmıştır. Proteomiklerin veteriner hekimlikte kullanımının beşeri hekimlikteki kullanımların gerisinde kalmasına rağmen son zamanlarda hayvan hastalıklarının patolojik yolaklarının araştırılmasında büyük bir ilgi alanı olmuştur. Son zamanlarda dünya çapında böbrek hastalıklarının nedenlerinin başında, glomerüler hastalıklar gelmektedir. Glomerüler hastalıkların teşhisinde kullanılabilecek idrar belirteçlerini belirlemek için insan ve hayvan modellerinde proteomik çalışmalar yapılmaktadır. Proteomik çalışmaların diğer çalışmalardan farkı, bir defada çok sayıda proteinin incelenmesine imkân sağlamasıdır. Yapılan proteomik araştırmalar sayesinde, interlökin-18, nötrofil jelatinaz ilişkili lipokalin, renal papiller antijen-1, böbrek hasar molekülü-1, simetrik dimetilarjinin, clusterin, cauxin, karaciğer tipi yağ asidi bağlayıcı protein, albümin, retinol bağlayıcı protein, sistatin C, N-asetil-β-d glukozaminidaz gibi çeşitli biyobelirteçler bulunmaktadır. Bu derlemede, hayvanlarda böbrek hastalıklarının erken teşhisinde biyobelirteç olarak proteomiklerin öneminden bahsedilmektedir.

Anahtar Kelimeler: Proteomikler; akut böbrek hasarı; kronik böbrek yetmezliği; böbrek
ABSTRACT
 Kidney failure is an important disease that occurs in animals of all ages, especially in older animals, which is manifested by a decrease in organ function. Chronic kidney failure, in particular, is characterized by irreversible reduction in kidney function and is the most common kidney disease. Early diagnosis in kidney diseases is important in terms of effective treatment applications. Diagnosis of chronic kidney disease is an important part of small animal practice. Creatinine is insufficient for early diagnosis of the disease. Today, many proteomic studies have been conducted aiming to determine the proteins formed by the effects of diseases, toxic agents and drugs and to clarify their functions. Although the use of proteomics in veterinary medicine lags behind human medical uses, it has recently been a major area of interest in the research of pathological pathways of animal diseases. Recently, glomerular diseases are the main causes of kidney diseases worldwide. In order to determine the urine markers that can be used in the diagnosis of glomerular diseases, proteomic studies are conducted in human and animal models. The difference of proteomic studies from other studies is that it allows the examination of a large number of proteins at a time. Due to proteomic research, there are various biomarkers such as interleukin-18, neutrophil gelatinase associated lipocalin, renal papillary antigen-1, kidney damage molecule-1, symmetric dimethylarginine, clusterin, cauxin, liver type fatty acid binding protein, albumin, retinol binding protein, cystatin C, N-acetyl-β-D glucosaminidase. In this review, the importance of proteomics as a biomarker in early diagnosis of kidney diseases in animals is mentioned.

Keywords: Proteomics; acute kidney injury; chronic renal failure; kidney
REFERENCES:
  1. Horgan RP, Kenny LC. Omic technologies: genomics, transcriptomics, proteomics and metabolomics. The Obstetrician & Gynaecologist. 2011;13(3):189-95. [Crossref] 
  2. Kurban S, Mehmetoğlu İ. [Proteomic]. Yeni Tıp Dergisi. 2010;27:70-5.
  3. Gündoğdu AK, Karahan AG. [Nutrigenomic technologies]. Gıda. 2008;33(4):183-91.
  4. Marko-Varga G. Proteomics principles and challenges. Pure Appl Chem. 2004;76(4): 829-37. [Crossref] 
  5. Goodacre R. Metabolomics-the way forward. Metabolomics. 2005;1:1-2. [Crossref] 
  6. Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, et al. The human proteome project: current state and future direction. Mol Cell Proteomics. 2011;10(7): M111.009993. [Crossref]  [PubMed]  [PMC] 
  7. Özcengiz G. [Proteomic: The most powerful technology of the post-genomic period]. ODTÜ Haber Bülteni. 2007;15:9-13.
  8. Başaran E, Aras S, Cansaran-Duman D. [General outlook and applications of genomics, proteomics and metabolomics]. Türk Hijyen ve Deneysel Biyoloji Dergisi. 2010;67(2):85-96.
  9. Eckersall PD, Bell R. Acute phase proteins: biomarkers of infection and inflammation in veterinary medicine. Vet J. 2010;185(1):23-7. [Crossref]  [PubMed] 
  10. Miller I. Protein seperation strategies. In: Eckersall D, Whitfield P, eds. Methods in Animal Proteomics. 1st ed. Chichester: John Wiley & Sons; 2011. p.41-76. [Crossref] 
  11. Köse Sİ, Maden M. [Urinary biomarkers: review]. Turkiye Klinikleri J Vet Sci. 2015;6(1):7-18. [Crossref] 
  12. Langston C. Acute uremia. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and the Cat. 7th ed. St. Louis, MO: Saunders Elsevier; 2009. p.1969-84.
  13. Segev G, Kass PH, Francey T, Cowgill LD. A novel clinical scoring system for outcome prediction in dogs with acute kidney injury managed by hemodialysis. J Vet Intern Med. 2008;22(2):301-8. [Crossref]  [PubMed] 
  14. Price R. Early markers of nephrotoxicity. Comp Clin Pathol. 2002;(11):2-7. [Crossref] 
  15. Lv Y, Cai G, Chen X. Applications of Urinary Proteomics in Renal Disease Research Using Animal Models. Adv Exp Med Biol. 2015;845:145-50. [Crossref]  [PubMed] 
  16. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007;177(4):361-8. [Crossref]  [PubMed]  [PMC] 
  17. Price SA, Davies D, Rowlinson R, Copley CG, Roche A, Falkenberg FW, et al. Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis. Toxicol Pathol. 2010;38(3):346-58. [Crossref]  [PubMed] 
  18. Krawczeski CD, Goldstein SL, Woo JG, Wang Y, Piyaphanee N, Ma Q, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011;58(22):2301-9. [Crossref]  [PubMed]  [PMC] 
  19. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(2): 127-32. [Crossref]  [PubMed] 
  20. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268(14):10425-32.
  21. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45(1):17-23. [Crossref]  [PubMed] 
  22. Yuen PS, Jo SK, Holly MK, Hu X, Star RA. Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses. Physiol Genomics. 2006;25(3):375-86. [Crossref]  [PubMed]  [PMC] 
  23. Segev G, Palm C, LeRoy B, Cowgill LD, Westropp JL. Evaluation of neutrophil gelatinase-associated lipocalin as a marker of kidney injury in dogs. J Vet Intern Med. 2013;27(6):1362-7. [Crossref]  [PubMed] 
  24. Nabity MB, Lees GE, Cianciolo R, Boggess MM, Steiner JM, Suchodolski JS. Urinary biomarkers of renal disease in dogs with X-linked hereditary nephropathy. J Vet Intern Med. 2012;26(2):282-93. [Crossref]  [PubMed] 
  25. Kai K, Yamaguchi T, Yoshimatsu Y, Kinoshita J, Teranishi M, Takasaki W. Neutrophil gelatinase-associated lipocalin, a sensitive urinary biomarker of acute kidney injury in dogs receiving gentamicin. J Toxicol Sci. 2013;38(2):269-77. [Crossref]  [PubMed] 
  26. Hsu WL, Lin YS, Hu YY, Wong ML, Lin FY, Lee YJ. Neutrophil gelatinase-associated lipocalin in dogs with naturally occurring renal diseases. J Vet Intern Med. 2014;28(2):437-42. [Crossref]  [PubMed]  [PMC] 
  27. Lee YJ, Hu YY, Lin YS, Chang CT, Lin FY, Wong ML, et al. Urine neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute canine kidney injury. BMC Vet Res. 2013;8:248. [Crossref]  [PubMed]  [PMC] 
  28. Yildiz R, Corum O, Atik O, Durna Corum D, Altan F, Ok M, et al. Changes in novel gastroıntestinal and renal injury markers in the blood plasma of sheep following increasing intravenous doses of tolfenamic acid. Acta Vet Hung. 2019;67(1):87-97. [Crossref]  [PubMed] 
  29. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2006;290(2):F517-29. [Crossref]  [PubMed] 
  30. Bland SK, Côté O, Clark ME, DeLay J, Bienzle D. Characterization of kidney injury molecule-1 in cats. J Vet Intern Med. 2014;28(5): 1454-64. [Crossref]  [PubMed]  [PMC] 
  31. Nabity MB. Traditional renal biomarkers and new approaches to diagnostics. Toxicol Pathol. 2018;46(8):999-1001. [Crossref]  [PubMed] 
  32. Relford R, Robertson, J, Clements C. Symmetric dimethylarginine: improving the diagnosis and staging of chronic kidney disease in small animals. Vet Clin North Am Small Anim Pract. 2016;46(6):941-60. [Crossref]  [PubMed] 
  33. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest. 1998;58(7):585-92. [Crossref]  [PubMed] 
  34. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta analysis. Am J Kidney Dis. 2002;40(2):221-6. [Crossref]  [PubMed] 
  35. García-Martínez JD, Martinez-Subiela S, Tvarijonaviciute A, Caldin M, Ceron JJ. Urinary ferritin and cystatin C concentrations at different stages of kidney disease in leishmaniotic dogs. Res Vet Sci. 2015;99:204-7. [Crossref]  [PubMed] 
  36. Miyagawa Y, Takemura N, Hirose H. Evaluation of the measurement of serum cystatin C by an enzyme-linked immunosorbent assay for humans as a marker of the glomerular filtration rate in dogs. J Vet Med Sci. 2009;71(9):1169-76. [Crossref]  [PubMed] 
  37. Kovarikova S. Urinary biomarkers of renal function in dogs and cats: a review. Veterinarni Medicina. 2015;60(11):589-602. [Crossref] 
  38. Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, et al. Impaired IL-18 processing protects caspase-1 deficient mice from ischemic acute renal failure. J Clin Invest. 2001;107(9):1145-52. [Crossref]  [PubMed]  [PMC] 
  39. Zheng J, Xiao Y, Yao Y, Xu G, Li C, Zhang Q, et al. Comparison of urinary biomarkers for early detection of acute kidney injury after cardiopulmonary bypass surgery in infants and young children. Pediatr Cardiol. 2013;34(4): 880-6. [Crossref]  [PubMed] 
  40. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16(10):3046-52. [Crossref]  [PubMed] 
  41. Leslie JA, Meldrum KK. The role of interleukin-18 in renal injury. J Surg Res. 2008;145(1): 170-5. [Crossref]  [PubMed] 
  42. Forterre S, Raila J, Schweigert FJ. Protein profiling of urine from dogs with renal disease using ProteinChip analysis. J Vet Diagn Invest. 2014;16(4):271-7. [Crossref]  [PubMed] 
  43. Smets PM, Meyer E, Maddens B, Duchateau L, Daminet S. Urinary markers in healthy young and aged dogs and dogs with chronic kidney disease. J Vet Intern Med. 2010;24(1):65-72. [Crossref]  [PubMed] 
  44. van Hoek I, Daminet S, Notebaert S, Janssens I, Meyer E. Immunoassay of urinary retinol binding protein as a putative renal marker in cats. J Immunol Methods. 2008;329(1-2):208-13. [Crossref]  [PubMed] 
  45. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol. 2002;34(5):427-31. [Crossref] 
  46. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 2010;28(5):463-9. [Crossref]  [PubMed] 
  47. Zhou X, Ma B, Lin Z, Qu Z, Huo Y, Wang J, et al. Evaluation of the usefulness of novel biomarkers for drug-induced acute kidney injury in beagle dogs. Toxicol Appl Pharmacol. 2014;280(1):30-5. [Crossref]  [PubMed] 
  48. Miyazaki M, Kamiie K, Soeta S, Taira H, Yamashita T. Molecular cloning and characterization of a novel carboxylesterase-like protein that is physiologically present at high concentrations in the urine of domestic cats (Felis catus). Biochem J. 2003;370(Pt 1):101-10. [Crossref]  [PubMed]  [PMC] 
  49. Miyazaki M, Soeta S, Yamagishi N, Taira H, Suzuki A, Yamashita T. Tubulointerstitial nephritis causes decreased renal expression and urinary excretion of cauxin, a major urinary protein of the domestic cat. Res Vet Sci. 2007;82(1):76-9. [Crossref]  [PubMed] 
  50. Furuhato N, Shiba K, Naro N. N acetyl βD- glucosaminidase. Nippon Rinsho. 1995;53(5):1267-76.
  51. Price RG. Measurement of N-acetyl beta-glucosaminidase and its isoeenzymes in urine methods and clinical applications. Eur J Clin Chem Clin Biochem. 1992;30(10):693-705.
  52. Bishop SA, Lucke VM, Stokes CR, Gruffydd-Jones TJ. Plasma and urine biochemical changes in cats with experimental immune complex glomerulonephritis. J Comp Pathol.1991;104(1):65-76. [Crossref] 
  53. Newman SJ, Confer AW, Paneiera RJ. Urinary system. In: McGavin MD, Zachary JF, eds. Pathologic Basis of Veterinary Disease. 4th ed. St Louis: Elsevier Mosby; 2006. p.613-91.
  54. Murgier P, Jakins A, Bexfield N, Archer J. Comparison of semiquantitative test strips, urine protein electrophoresis, and immunoturbidimetric assay for measuring microalbuminuria in dogs. Vet Clin Pathol. 2009;38(4): 485-92. [Crossref]  [PubMed] 
  55. Erdoğan MB, Demirpençe Ö, Yıldırım M. [Early markers used in the diagnosis of acute renal failure after cardiovascular surgery]. ACU Sağlık Bil Derg. 2016(1):14-19.

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com